{"mainPropery":{"diseaseId":9676,"diseaseName":"Miyoshi myopathy","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9676/miyoshi-myopathy","synonyms":["Muscular dystrophy, distal, late onset, autosomal recessive","MM","Miyoshi distal myopathy"],"synonyms-with-source":[{"name":"Muscular dystrophy, distal, late onset, autosomal recessive"},{"name":"MM"},{"name":"Miyoshi distal myopathy"}],"identifiers":[{"identifierType":"OMIM","identifierId":"254130"},{"identifierType":"OMIM","identifierId":"613318"},{"identifierType":"OMIM","identifierId":"613319"},{"identifierType":"ORPHANET","identifierId":"45448"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":87,"resourceName":"Muscular Dystrophy Family Foundation","abbreviation":"","address1":"P.O. Box 776","address2":"","address3":"","address4":"","address5":"","city":"Carmel","state":"IN","zip":"46082","country":"United States","phone":"+1-317-615-9140","tty":"","tollFree":"","fax":"","email":"info@mdff.org","url":"https://mdff.org/","freeText":"MDFF provides financial assistance, quality programs and services for the Muscular Dystrophy community in Indiana."},{"resourceID":663,"resourceName":"Jain Foundation","abbreviation":"","address1":"9706 4th Ave NE","address2":"Ste 101","address3":"","address4":"","address5":"","city":"Seattle","state":"WA","zip":"98115","country":"United States","phone":"425-882-1492","tty":"","tollFree":"","fax":"","email":"patients@jain-foundation.org","url":"https://www.jain-foundation.org/","freeText":""},{"resourceID":935,"resourceName":"Muscular Dystrophy Association","abbreviation":"MDA","address1":"222 S Riverside Plaza","address2":"Suite 1500","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60606","country":"United States","phone":"","tty":"","tollFree":"1-833-275-6321 (Helpline)","fax":"","email":"resourcecenter@mdausa.org","url":"https://www.mda.org","freeText":""},{"resourceID":936,"resourceName":"Muscular Dystrophy UK","abbreviation":"","address1":"61A Great Suffolk Street","address2":"","address3":"","address4":"","address5":"","city":"London","state":"","zip":" SE1 0BU","country":"United Kingdom","phone":" (+44) 0 020 7803 4800","tty":"","tollFree":"0800 652 6352 (Helpline)","fax":"","email":"info@musculardystrophyuk.org","url":"https://www.musculardystrophyuk.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"Online Mendelian Inheritance in Man (OMIM) is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n<a href='http://www.omim.org/254130' target='_blank'>http://www.ncbi.nlm.nih.gov/omim/254130</a><br /><a href='http://www.omim.org/613318' target='_blank'>http://www.ncbi.nlm.nih.gov/omim/613318</a><br /><a href='http://www.omim.org/613319' target='_blank'>http://www.ncbi.nlm.nih.gov/omim/613319</a><br />","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/pubmed/?term=Miyoshi+myopathy+%5Bti%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Miyoshi myopathy. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Miyoshi+myopathy%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Miyoshi myopathy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/miyoshi-myopathy' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Miyoshi myopathy. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":111,"resourceId":972,"resourceName":"Centers for Mendelian Genomics","descriptionText":"The <a href='http://mendelian.org/' target='_blank'>Centers for Mendelian Genomics</a> program is working to discover the causes of rare genetic disorders. For more information about applying to the research study, please visit their website.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":288,"resourceId":663,"resourceName":"Jain Foundation","descriptionText":"<a href='http://jain-foundation.org/patient-physician-resources/clinical-studies-and-trials ' target='_blank'>The Jain Foundation</a> provides information on clinical trials and research studies for dysferlinopathy.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":289,"resourceId":663,"resourceName":"Jain Foundation","descriptionText":"<a href='http://jain-foundation.org/patient-physician-resources/learning-center ' target='_blank'>The Jain Foundation Learning Center</a> provides basic information on this condition. ","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":290,"resourceId":663,"resourceName":"Jain Foundation","descriptionText":"<a href='http://jain-foundation.org/patient-physician-resources/diagnostic-resources ' target='_blank'>The Jain Foundation</a> sponsors genetic testing to confirm the diagnosis of dysferlinopathy.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":291,"resourceId":663,"resourceName":"Jain Foundation","descriptionText":"<a href='http://jain-foundation.org/patient-physician-resources/physician-referrals ' target='_blank'>The Jain Foundation</a> provides a list of doctors who are knowledgeable about diagnosing dysferlinopathy. ","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":292,"resourceId":663,"resourceName":"Jain Foundation","descriptionText":"<a href='http://jain-foundation.org/our-dysferlin-research-institute/conferences ' target='_blank'>The Jain Foundation</a> holds an annual conference dedicated to dysferlinopathy research.  ","resourceClassificationName":"News & Events","resourceClassificationSectionName":"Other Conferences"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C1850808' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=45448' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1303/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:254130' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Miyoshi myopathy. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Miyoshi myopathy:<br />\r\n<a href='http://jain-foundation.org/patient-physician-resources/patient-registration' target='_blank'>Dysferlin Registry </a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":4295,"questionText":"What is Miyoshi myopathy?","answerText":"<strong>Miyoshi myopathy&nbsp;</strong>is a type of <a href=\"http://ghr.nlm.nih.gov/glossary=musculardystrophy\" target=\"_blank\">muscular dystrophy</a> characterized by muscle weakness and atrophy (wasting), mainly in the distal parts of the legs.[3235]&nbsp;The first symptoms typically begin in&nbsp;young adulthood (on average 20 years of age) and include weakness and atrophy of the calves (sometimes asymmetrically), leading to inability to jump, run or walk on tiptoes. Over a period of years, the weakness and atrophy typically spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength. Blood exams show an elevation of the <a href=\"https://labtestsonline.org/tests/creatine-kinase-ck\" target=\"_blank\">creatine kinase (CK)</a>  often 10-100 times above the normal values.[3235] It is caused by variations (mutations) in the <a href=\"http://ghr.nlm.nih.gov/gene/DYSF\" target=\"_blank\"><em>DYSF</em></a> gene. Inheritance is&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>.[3236] Management may include physical therapy, use of mechanical aids, surgical intervention for orthopedic complications, respiratory aids, and social and emotional support.[3235]<br />\r\n<br />\r\nMiyoshi myopathy is part of the group of diseases known as&nbsp; \"<a href=\"https://rarediseases.info.nih.gov/diseases/2003/dysferlinopathy\" target=\"_blank\">Dysferlinopathies</a>\", which are caused by <em>DYSF</em> pathogenic variants. <br />\r\n<br />","dateModified":"2018-07-02T00:00:00"},"basicQuestions":[{"questionId":4296,"questionText":"What are the signs and symptoms of Miyoshi myopathy?","answerText":"The disease have slow progression. Onset of signs and symptoms is typically in mid to late childhood or early-adulthood, (average age&nbsp;at onset of 19 years), and may include:[3235]<br />\r\n<ul>\r\n    <li>Muscle weakness and atrophy (wasting),&nbsp;most marked in the distal parts of the legs, especially the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/17238.htm\" target=\"_blank\" style=\"font-size: 12pt;\">gastrocnemius (calf) and soleus (Achilles tendon)&nbsp;muscles</a><span style=\"font-size: 12pt;\">, specially in young adults</span></li>\r\n    <li>Inability to stand on tiptoe, retaining the ability to stand on the heels</li>\r\n    <li>Slow progression of weakness and atrophy spreading to the thighs and gluteal muscles, at which time climbing stairs, standing, and walking become difficult</li>\r\n    <li>Mildly loss of muscular mass in&nbsp; forearms with decrease in grip strength; the small muscles of the hands are not affected</li>\r\n    <li>Weakness of the shoulder girdle muscles, which may occur on one side than the other.</li>\r\n</ul>","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4297,"questionText":"What causes Miyoshi myopathy?","answerText":"Miyoshi myopathy is caused by pathogenic variants (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/DYSF\" target=\"_blank\"><em>DYSF</em></a> gene, which encodes the dysferlin protein, a component of muscular fiber membranes. The presence and/or&nbsp;activity of the dysferlin protein is decreased or absent in individuals who have Miyoshi myopathy.[3236] This&nbsp;leads to abnormalities in the integrity of the muscle fiber membrane and problems with membrane repair. Mutations in the same&nbsp;gene are also involved in autosomal recessive&nbsp;<a href=\"https://rarediseases.info.nih.gov/GARD/Condition/8574/LGMD2B.aspx\" target=\"_blank\">limb-girdle muscular dystrophy type 2B</a> (LGMD2B) and other diseases. The group of diseases caused by mutations in the DYSF gene are referred as \"Dysferlinopathy\".[3235]","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3236,"authors":"","articleTitle":"Miyoshi myopathy","bookWebsiteJournalTitle":"Orphanet","date":"2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=45448","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4298,"questionText":"How is Miyoshi myopathy inherited?","answerText":"Miyoshi myopathy&nbsp;is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[3235] Individuals have two copies&nbsp;of each gene (one copy inherited from each parent). In an individual affected with an autosomal recessive condition, both copies of the responsible gene have mutations. This means that each of the parents of an affected individual carry one mutated copy of the gene, and are therefore referred to as \"carriers.\" Carriers of an autosomal recessive condition typically do not show signs or symptoms of the condition. When two carriers for the same condition have children together, each child has a 1 in 4 (25%) risk to have the condition, a 1 in 2 (50%) risk to be a carrier like each of the parents, and a 1 in 4 chance to not have the condition <em>and</em> not be a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the disease-causing mutations in the family are known.","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4302,"questionText":"How is Miyoshi myopathy diagnosed?","answerText":"Characteristics that may make the diagnosis of Miyoshi myopathy likely are:<br>\r\n<ul>\r\n<li>Mid- to late-childhood or early-adult onset of signs and symptoms \r\n<li>Early and predominant involvement of the calf muscles \r\n<li>Slow progression \r\n<li>Elevation of serum <a href=\"http://www.mda.org/publications/Quest/q71ss-cktest.html\" target=_blank>creatine kinase (CK) concentration</a>, often 10-100 times normal \r\n<li>Primarily myogenic pattern on EMG (<a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/9741.htm\" target=_blank>electromyography</a>) \r\n<li>Biopsy evidence of a chronic, active myopathy without rimmed vacuoles[3235]</li></ul>\r\nDiagnosis typically depends on a combination of muscle biopsy and genetic testing. Muscle biopsy almost always indicates a primary dysferlinopathy (a disorder involving dysferlin, the protein absent or decreased in individuals with Miyoshi myopathy and limb-girdle muscular dystrophy type 2B). Molecular genetic testing of DYSF, the only gene associated with dysferlinopathy, is clinically available.[3235]","dateModified":"2011-06-06T15:34:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4299,"questionText":"How might Miyoshi myopathy be treated?","answerText":"There is currently no cure or definitive treatment for Miyoshi myopathy. Management depend on the specific signs and symptoms, and is aimed to prolong survival and improve quality of life:.[3235] <br />\r\n<ul>\r\n    <li>Physical therapy and stretching exercises to promote mobility and prevent contractures</li>\r\n    <li>Use of mechanical aids such as canes, walkers, orthotics, and wheelchairs as needed to help ambulation and mobility</li>\r\n    <li>Surgical intervention as needed for orthopedic complications such as foot deformity and scoliosis</li>\r\n    <li>Use of respiratory aids when indicated</li>\r\n    <li>Social and emotional support </li>\r\n</ul>\r\nBecause&nbsp; dysferlinopathies are progressive conditions, rehabilitative interventions should be focused on slowing down the of muscle weakness and wasting progression, rather than increasing muscle strength and walking capacity at the risk of causing irreversible muscle damage. Gene therapies are under investigation.[14760]","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14760,"authors":"Begam M, Collier AF, Mueller AL, Roche R, Galen SS & Roche JA","articleTitle":"Diltiazem improves contractile properties of skeletal muscle in dysferlin-deficient BLAJ mice, but does not reduce contraction-induced muscle damage","bookWebsiteJournalTitle":"Physiological Reports","date":"2018","volume":"6(11)","pages":"e13727","url":"https://www-ncbi-nlm-nih-gov.ezproxy.nihlibrary.nih.gov/pmc/articles/PMC5995314/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":2003,"relatedDiseaseName":"Dysferlinopathy","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":30214,"abbreviatedInquiry":"My brother and I have similar symptoms and I was recently informed that it was Miyoshi distal myopathy. Could you please provide some of the latest information on this disease?","caseQuestions":[{"questionId":4295,"questionText":"What is Miyoshi myopathy?","answerText":"<strong>Miyoshi myopathy&nbsp;</strong>is a type of <a href=\"http://ghr.nlm.nih.gov/glossary=musculardystrophy\" target=\"_blank\">muscular dystrophy</a> characterized by muscle weakness and atrophy (wasting), mainly in the distal parts of the legs.[3235]&nbsp;The first symptoms typically begin in&nbsp;young adulthood (on average 20 years of age) and include weakness and atrophy of the calves (sometimes asymmetrically), leading to inability to jump, run or walk on tiptoes. Over a period of years, the weakness and atrophy typically spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength. Blood exams show an elevation of the <a href=\"https://labtestsonline.org/tests/creatine-kinase-ck\" target=\"_blank\">creatine kinase (CK)</a>  often 10-100 times above the normal values.[3235] It is caused by variations (mutations) in the <a href=\"http://ghr.nlm.nih.gov/gene/DYSF\" target=\"_blank\"><em>DYSF</em></a> gene. Inheritance is&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>.[3236] Management may include physical therapy, use of mechanical aids, surgical intervention for orthopedic complications, respiratory aids, and social and emotional support.[3235]<br />\r\n<br />\r\nMiyoshi myopathy is part of the group of diseases known as&nbsp; \"<a href=\"https://rarediseases.info.nih.gov/diseases/2003/dysferlinopathy\" target=\"_blank\">Dysferlinopathies</a>\", which are caused by <em>DYSF</em> pathogenic variants. <br />\r\n<br />","dateModified":"2018-07-02T00:00:00","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3236,"authors":"","articleTitle":"Miyoshi myopathy","bookWebsiteJournalTitle":"Orphanet","date":"2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=45448","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4296,"questionText":"What are the signs and symptoms of Miyoshi myopathy?","answerText":"The disease have slow progression. Onset of signs and symptoms is typically in mid to late childhood or early-adulthood, (average age&nbsp;at onset of 19 years), and may include:[3235]<br />\r\n<ul>\r\n    <li>Muscle weakness and atrophy (wasting),&nbsp;most marked in the distal parts of the legs, especially the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/17238.htm\" target=\"_blank\" style=\"font-size: 12pt;\">gastrocnemius (calf) and soleus (Achilles tendon)&nbsp;muscles</a><span style=\"font-size: 12pt;\">, specially in young adults</span></li>\r\n    <li>Inability to stand on tiptoe, retaining the ability to stand on the heels</li>\r\n    <li>Slow progression of weakness and atrophy spreading to the thighs and gluteal muscles, at which time climbing stairs, standing, and walking become difficult</li>\r\n    <li>Mildly loss of muscular mass in&nbsp; forearms with decrease in grip strength; the small muscles of the hands are not affected</li>\r\n    <li>Weakness of the shoulder girdle muscles, which may occur on one side than the other.</li>\r\n</ul>","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4297,"questionText":"What causes Miyoshi myopathy?","answerText":"Miyoshi myopathy is caused by pathogenic variants (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/DYSF\" target=\"_blank\"><em>DYSF</em></a> gene, which encodes the dysferlin protein, a component of muscular fiber membranes. The presence and/or&nbsp;activity of the dysferlin protein is decreased or absent in individuals who have Miyoshi myopathy.[3236] This&nbsp;leads to abnormalities in the integrity of the muscle fiber membrane and problems with membrane repair. Mutations in the same&nbsp;gene are also involved in autosomal recessive&nbsp;<a href=\"https://rarediseases.info.nih.gov/GARD/Condition/8574/LGMD2B.aspx\" target=\"_blank\">limb-girdle muscular dystrophy type 2B</a> (LGMD2B) and other diseases. The group of diseases caused by mutations in the DYSF gene are referred as \"Dysferlinopathy\".[3235]","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3236,"authors":"","articleTitle":"Miyoshi myopathy","bookWebsiteJournalTitle":"Orphanet","date":"2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=45448","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4298,"questionText":"How is Miyoshi myopathy inherited?","answerText":"Miyoshi myopathy&nbsp;is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[3235] Individuals have two copies&nbsp;of each gene (one copy inherited from each parent). In an individual affected with an autosomal recessive condition, both copies of the responsible gene have mutations. This means that each of the parents of an affected individual carry one mutated copy of the gene, and are therefore referred to as \"carriers.\" Carriers of an autosomal recessive condition typically do not show signs or symptoms of the condition. When two carriers for the same condition have children together, each child has a 1 in 4 (25%) risk to have the condition, a 1 in 2 (50%) risk to be a carrier like each of the parents, and a 1 in 4 chance to not have the condition <em>and</em> not be a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the disease-causing mutations in the family are known.","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4302,"questionText":"How is Miyoshi myopathy diagnosed?","answerText":"Characteristics that may make the diagnosis of Miyoshi myopathy likely are:<br>\r\n<ul>\r\n<li>Mid- to late-childhood or early-adult onset of signs and symptoms \r\n<li>Early and predominant involvement of the calf muscles \r\n<li>Slow progression \r\n<li>Elevation of serum <a href=\"http://www.mda.org/publications/Quest/q71ss-cktest.html\" target=_blank>creatine kinase (CK) concentration</a>, often 10-100 times normal \r\n<li>Primarily myogenic pattern on EMG (<a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/9741.htm\" target=_blank>electromyography</a>) \r\n<li>Biopsy evidence of a chronic, active myopathy without rimmed vacuoles[3235]</li></ul>\r\nDiagnosis typically depends on a combination of muscle biopsy and genetic testing. Muscle biopsy almost always indicates a primary dysferlinopathy (a disorder involving dysferlin, the protein absent or decreased in individuals with Miyoshi myopathy and limb-girdle muscular dystrophy type 2B). Molecular genetic testing of DYSF, the only gene associated with dysferlinopathy, is clinically available.[3235]","dateModified":"2011-06-06T15:34:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4299,"questionText":"How might Miyoshi myopathy be treated?","answerText":"There is currently no cure or definitive treatment for Miyoshi myopathy. Management depend on the specific signs and symptoms, and is aimed to prolong survival and improve quality of life:.[3235] <br />\r\n<ul>\r\n    <li>Physical therapy and stretching exercises to promote mobility and prevent contractures</li>\r\n    <li>Use of mechanical aids such as canes, walkers, orthotics, and wheelchairs as needed to help ambulation and mobility</li>\r\n    <li>Surgical intervention as needed for orthopedic complications such as foot deformity and scoliosis</li>\r\n    <li>Use of respiratory aids when indicated</li>\r\n    <li>Social and emotional support </li>\r\n</ul>\r\nBecause&nbsp; dysferlinopathies are progressive conditions, rehabilitative interventions should be focused on slowing down the of muscle weakness and wasting progression, rather than increasing muscle strength and walking capacity at the risk of causing irreversible muscle damage. Gene therapies are under investigation.[14760]","dateModified":"2018-07-02T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":3235,"authors":"Aoki M","articleTitle":"Dysferlinopathy","bookWebsiteJournalTitle":"GeneReviews","date":"2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1303/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14760,"authors":"Begam M, Collier AF, Mueller AL, Roche R, Galen SS & Roche JA","articleTitle":"Diltiazem improves contractile properties of skeletal muscle in dysferlin-deficient BLAJ mice, but does not reduce contraction-induced muscle damage","bookWebsiteJournalTitle":"Physiological Reports","date":"2018","volume":"6(11)","pages":"e13727","url":"https://www-ncbi-nlm-nih-gov.ezproxy.nihlibrary.nih.gov/pmc/articles/PMC5995314/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2567,"questionText":"How can I find a genetics professional in my area?","answerText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by  the <a href=\"https://www.acmg.net/ACMG/Find_Genetic_Services/ACMG/ISGweb/FindaGeneticService.aspx?hkey=720856ab-a827-42fb-a788-b618b15079f9\" target=\"_blank\">American College of Medical Genetics</a>&nbsp;and the&nbsp;<a href=\"https://www.findageneticcounselor.com/\" target=\"_blank\">National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also <a href=\"http://ghr.nlm.nih.gov/handbook/consult?show=all\" target=\"_blank\">learn more about genetic consultations</a> from Genetics Home Reference.","dateModified":"2017-12-06T00:00:00","references":[]},{"questionId":4303,"questionText":"How can I find the most up-to-date information about Miyoshi myopathy?","answerText":"You can find relevant articles on Miyoshi myopathy&nbsp;through PubMed, a searchable database of biomedical journal articles. Although not all of the articles are available for free online, most articles listed in PubMed have a summary available. To obtain the full article, contact a medical/university library or your local library for interlibrary loan. You can also order articles online through the publisher’s Web site. Using \"Miyoshi myopathy\" as your search term should help you locate articles. Use the Limits or Advanced Search features to narrow your search results. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/\" target=_blank>Click here</a> to perform a search.<br><br>The National Library of Medicine (NLM) Web site has a page for locating libraries in your area that can provide direct access to these journals (print or online). The Web page also describes how you can get these articles through interlibrary loan and Loansome Doc (an NLM document-ordering service). You can access this page at the following link: <a href=\"http://nnlm.gov/members/\" target=_blank>http://nnlm.gov/members/</a>. You can also contact the NLM toll-free at 888-346-3656 to locate libraries in your area.<br><br>The U.S. National Institutes of Health, through the National Library of Medicine, developed <a href=\"http://www.clinicaltrials.gov/\" target=_blank>ClinicalTrials.gov</a> to provide patients, family members, and members of the public with current information on clinical research studies. To find trials for individuals with Miyoshi myopathy, click on the link above and use \"Miyoshi myopathy\" as your search term. After you click on a study, review its \"eligibility\" criteria to determine its appropriateness. Use the study’s contact information to learn more. Check this site often for regular updates.<br><br>You can also contact the Patient Recruitment and Public Liaison (PRPL) Office at the National Institutes of Health (NIH). We recommend calling the toll-free number listed below to speak with a specialist, who can help you determine if you are eligible for any clinical trials. If you are located outside the United States, and would like to be contacted via telephone, you will need to provide your telephone number in full, including area code and international dialing prefix.<br>Patient Recruitment and Public Liaison Office<br>NIH Clinical Center<br>Bethesda, Maryland 20892-2655<br>Toll-free: 800-411-1222<br>Fax: 301-480-9793<br>Email: <a href=\"mailto:prpl@mail.cc.nih.gov\">prpl@mail.cc.nih.gov<br></a>Web site: <a href=\"http://clinicalcenter.nih.gov/\" target=_blank>http://clinicalcenter.nih.gov/</a>","dateModified":"2011-04-05T11:47:00","references":[]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":6254,"phenoTypeName":"Adult onset","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5279,"phenoTypeName":"Difficulty standing","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11432,"phenoTypeName":"Difficulty walking","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4519,"phenoTypeName":"Distal upper limb amyotrophy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5304,"phenoTypeName":"Exercise-induced myalgia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5316,"phenoTypeName":"Pelvic girdle muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4515,"phenoTypeName":"Proximal amyotrophy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5300,"phenoTypeName":"Quadriceps muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6231,"phenoTypeName":"Shoulder girdle muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4241,"phenoTypeName":"Tibialis atrophy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3434,"phenoTypeName":"Tibialis muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3444,"phenoTypeName":"Calf muscle hypertrophy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":991,"phenoTypeName":"Decreased/absent ankle reflexes","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5312,"phenoTypeName":"Deposits immunoreactive to beta-amyloid protein","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3466,"phenoTypeName":"Foot dorsiflexor weakness","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":1629,"phenoTypeName":"Loss of ability to walk","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":383,"phenoTypeName":"Toe walking","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9442,"phenoTypeName":"Triceps weakness","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":4923,"phenoTypeName":"Decreased Achilles reflex","percentRanges":"-"},{"phenoTypeId":6235,"phenoTypeName":"Difficulty climbing stairs","percentRanges":"-"},{"phenoTypeId":4906,"phenoTypeName":"Difficulty running","percentRanges":"-"},{"phenoTypeId":5271,"phenoTypeName":"Distal amyotrophy","percentRanges":"-"},{"phenoTypeId":5216,"phenoTypeName":"Distal muscle weakness","percentRanges":"-"},{"phenoTypeId":10933,"phenoTypeName":"Elevated serum creatine kinase","percentRanges":"-"},{"phenoTypeId":13670,"phenoTypeName":"Lower limb muscle weakness","percentRanges":"-"},{"phenoTypeId":14235,"phenoTypeName":"Muscle fibrillation","percentRanges":"-"},{"phenoTypeId":6240,"phenoTypeName":"Muscular dystrophy","percentRanges":"-"},{"phenoTypeId":4908,"phenoTypeName":"Quadriceps muscle atrophy","percentRanges":"-"},{"phenoTypeId":7381,"phenoTypeName":"Variable expressivity","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Miyoshi_myopathy"}